Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
Apple Turns 50: From Garage Startup to AI Crossroads 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
NEW ORLEANS, Dec. 23, 2016 -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until January 9, 2017 to file lead plaintiff applications in a securities class action lawsuit against Impax Laboratories Inc. (Nasdaq:IPXL), if they purchased the Company’s securities between February 20, 2014 through November 3, 2016, inclusive (the “Class Period”). This action is pending in the United States District Court for the Districts of New Jersey and California.
What You May Do
If you purchased securities of Impax and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by January 9, 2017.
About the Lawsuit
Impax and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On November 3, 2016, Bloomberg reported that an “antitrust investigation by the Justice Department, begun about two years ago, now spans more than a dozen companies,” including Impax, “and about two dozen drugs.” The article further stated that a “grand jury probe is examining whether some executives agreed with one another to raise prices, and the first charges could emerge by the end of the year.” Additionally, according to Bloomberg, “[g]eneric drug companies are also contending with a civil price-fixing investigation by [the] Connecticut Attorney General.”
About Kahn Swick & Foti, LLC
KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 206 Covington St. Madisonville, LA 70447
